Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Huntington's disease is an autosomal dominant disease which presents with striatal and cortical degeneration causing involuntary movements, dementia and emotional changes. We employed 16‐week‐old transgenic Huntington mice (R6/1 line developed by Bates and coworkers) that express exon 1 of the mutant human Huntington gene with 115 CAG triplet repeats. At this age, R6/1 mice do not exhibit an overt neurological phenotype nor any striatal neuronal loss. Using microdialysis, we monitored basal and intrastriatal N‐methyl d‐aspartate (NMDA, 100 µ m, 15 min)‐ and KCl (100 m m, 15 min)‐induced increases in local aspartate, glutamate and GABA release in halothane‐anaesthetized transgenic mice and wild‐type controls. Basal striatal dialysate glutamate levels were reduced by 42% in R6/1 mice whilst aspartate and GABA levels did not differ from those observed in control mice. Intrastriatal NMDA was associated with significantly greater aspartate (at 15 min) and GABA (at 30 min) levels in the R6/1 mice compared to controls, whilst glutamate release rapidly increased to the same extent in both groups. Intrastriatal KCl was associated with enhanced increases (30 min) in local aspartate and glutamate release in the R6/1 mice above those observed in controls whilst the rapid increase (15 min) in GABA release was similar in both groups. The results provide compelling evidence for specific alterations in both basal, as well as NMDA‐ and KCl‐induced, release of striatal amino acid neurotransmitters in this transgenic model of Huntington's disease, even in the absence of manifest neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Cha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504 · cited 1×
“The enhanced responsivity to striatal NMDA is unlikely to be due to increased receptor number on individual neurons as there are no changes in NMDA receptor binding in R6/1 and R6/2 mice (Cha et al., 1998, 1999).”
BackgroundNonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G. P., & Davies, S. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110078997 · Cited by 430 · cited 2×
“The normal function of huntingtin is unknown, but it has been implicated in cytoskeletal functions and traf®cking of synaptic vesicles (DiFiglia et al., 1995; Velier et al., 1998).”
BackgroundHansson, O., Petersén, Å., Leist, M., Nicotera, P., Castilho, R. F., & Brundin, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8727 · Cited by 228
Self-citation
Cited by
Cepeda, C., Hurst, R. S., Calvert, C. R., Hernández-Echeagaray, E., Nguyen, O. K., Jocoy, E., Christian, L. J., Ariano, M. A., & Levine, M. S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-00961.2003 · Cited by 321
Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice
Liévens, J.-C., Woodman, B., Mahal, A., Spasic-Boscovic, O., Samuel, D., Kerkerian-Le Goff, L., & Bates, G. P. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0430 · Cited by 313
The corticostriatal pathway in Huntington's disease
CEPEDA, C., WU, N., ANDRE, V, CUMMINGS, D., & LEVINE, M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.001 · Cited by 310
Orexin loss in Huntington's disease
Petersén, Å., Gil, J., Maat-Schieman, M. L. C., Björkqvist, M., Tanila, H., Araújo, I. M., Smith, R., Popovic, N., Wierup, N., Norlén, P., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi004 · Cited by 271
Self-citationDopamine and Glutamate in Huntington's Disease: A Balancing Act
André, V. M., Cepeda, C., & Levine, M. S. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00134.x · Cited by 189
“Basal striatal glutamate levels were also reduced by 43% in R6/1 mice at 16 weeks [84].”
Background
Metadata
- Authors
- NicNiocaill, B., Haraldsson, B., Hansson, O., O'connor, W. T., & Brundin, P.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2001-01
- Volume
- 13
- Issue
- 1
- Pages
- 206-210
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W2104064731
- Cited by
- 90
- References
- 5
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. https://app.cochat.ai/papers/10.1046/j.0953-816x.2000.01379.x
- The paper
- NicNiocaill, B., Haraldsson, B., Hansson, O., O'connor, W. T., & Brundin, P. (2001). Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. European Journal of Neuroscience. https://doi.org/10.1046/j.0953-816x.2000.01379.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.